ABGSC acted as sole financial advisor in connection with Promore Pharma’s SEK 60.1m guaranteed rights issue

On 2 December 2019, Promore Pharma AB (publ) (“Promore Pharma”) announced the completion of a guaranteed rights issue, issuing 16,193,272 new shares at a subscription price of SEK 3.71, resulting in gross proceeds of SEK 60.1m.
Promore Pharma intends to use the proceeds for the following activities:
• Complete the ongoing Phase IIb study related to LL-37 (HEAL LL-37)
• Complete preparations for the planned Phase III study pertaining to PXL01 (PHSU03)
• Patent related costs
• General corporate purposes, including central and administrative costs